Filtered By:
Source: Mass Device
Management: Mergers and Aquisitions
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 36 results found since Jan 2013.
Perfuze raises $3m seed round for Millipede stroke catheter
Perfuze said today that it raised more than $3 million for the Millipede catheter it’s developing to treat ischemic stroke.
Although not quite in stealth mode, the Galway, Ireland-based firm is close-mouthed about its technology. CEO Wayne Allen and CTO Liam Mullins (who co-founded Embo Medical before its in 2015, $YY acquisition by C.R. Bard in 2015) founded Perfuze last year.
The €3 million ($3.4 million) seed round, earmarked for Millipede development, was led by European VC shop Earlybird. MedFocus, Enterprise Ireland and an Irish syndicate of medtech veterans and stroke physicians also participated, Pe...
Source: Mass Device - January 29, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Featured Funding Roundup Neurological Perfuze Stroke Source Type: news
J&J’s Biosense Webster buys Coherex Medical and its WaveCrest anti-stroke device
Johnson & Johnson (NYSE:JNJ) subsidiary Biosense Webster said today that it acquired Coherex Medical for an undisclosed amount.
Salt Lake City-based Coherex makes the Wavecrest anti-stroke device, which is designed to occlude the heart’s left atrial appendage to prevent blood clots from forming that could cause stroke.
“The addition of the Coherex WaveCrest system complements our comprehensive portfolio of therapeutic solutions for patients suffering from atrial fibrillation who not only suffer from reduced quality of life but also face a significantly greater risk of a stroke,” group chairman Shlomi...
Source: Mass Device - November 20, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Implants Cardiovascular Mergers & Acquisitions BioSense Webster Inc. Coherex Medical Johnson & Johnson Source Type: news
MassDevice Q & A: Claret Medical ’ s Azin Parhizgar on trying to make TAVR safer
Cerebral protection developer Claret Medical recently won FDA de novo clearance for its Sentinel device designed to trap blood clots and prevent stroke during heart valve replacement procedures.
The Sentinel uses a pair of filters, 1 in the brachiocephalic artery another in the left common carotid artery, to trap debris released during transcatheter aortic valve replacement that could cause a cerebral embolism.
The device has seen a rough road to approval, however, after missing the primary efficacy endpoint in its pivotal trial. Despite that, the device saw nearly unanimous support from an FDA advisory panel and was c...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Neurological Surgical Vascular Claret Medical Inc. Source Type: news
J & J ’ s Cerenovus launches Galaxy G3 mini embolic coil, touts Arise II Embotrap study data
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus division this week announced the launch of its Galaxy G3 Mini embolic coil and released data from a study of its Embotrap device designed to remove clots from the brain following ischemic stroke.
The Galaxy G3 Mini coils are designed to be approximately 25% softer than the Galaxy G3 xsft coils, with an ultra-low coil profile and a primary wind diameter of 0.009 inches, which Cerenovus said is the lowest profile available in its Spectra line.
The newly launched coil is designed to have a random complex shape to make it comformable and enable the device to seek and fill open...
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Catheters Clinical Trials Neurological Vascular cerenovus johnsonandjohnson Source Type: news
Medtronic pays $150m for Medina Medical
Medtronic (NYSE:MDT) yesterday said it agreed to pay $150 million to acquire Medina Medical and its embolization coil for treating brain aneurysms.
The Medina device is a self-expanding mesh designed to fill the inside of an aneurysm. Menlo Park, Calif.-based Medina won CE Mark approval in the European Union for the device in September 2014, a month after naming ex-Foundry partner Erik Engelson to be its new CEO. Back in October 2012, the company raised more than $6.5 million in an equity offering that aimed to raise $9.5 million.
Medtronic said it already owned a stake in Medina, meaning a pre-tax gain for its 2n...
Source: Mass Device - September 1, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Neurological Vascular Medina Medical medtronic Source Type: news
Medtronic acquires stent retriever cover-dev Lazarus Effect for $100m
Medtronic (NYSE:MDT) said today it acquired Campbell, Calif.-based stent-retriever cover developer Lazarus Effect for $100 million in an all-cash transaction.
Lazarus’ Cover device is designed to wrap stent retriever devices with a novel nitinol “mesh cover” that folds over the retreiver during clot retrieval and “candy wraps” the stent with the clot contained, Fridely, Minn.-based Medtronic said.
“With this acquisition, Medtronic reinforces its commitment to providing innovative solutions to clinicians and patients fighting stroke. Lazarus Effect’s ‘mesh cover’ techno...
Source: Mass Device - September 28, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Mergers & Acquisitions Stents Vascular Medtronic Source Type: news
Codman Neuro acquires Neuravi
Johnson & Johnson (NYSE:JNJ) business unit Codman Neuro said today it acquired Neuravi and its portfolio of neurovascular therapy technology for an undisclosed amount.
Neuravi produces the EmboTrap and EmboTrap II revascularization platforms designed capture clots and allow blood flow to resume immediately after the clot has been secured in patients who have experienced a stroke.
J&J’s Codman Neuro said that the acquisition, along with its recent Pulsar Vascular buy, demonstrates the company’s “strong commitment to delivering innovative products for stroke therapy,” according to a press ...
Source: Mass Device - April 10, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Neurological Codman Neuro Neuravi Limited Source Type: news
Johnson & Johnson hosts launch party for Cerenovus neurovascular biz
Johnson & Johnson (NYSE:JNJ) said today it launched its Cerenovus brand, which combined its Pulsar Vascular and Neuravi acquisitions and its remaining Codman Neuro neurological portfolio.
Cerenovus was launched at the European Society of Minimally Invasive Neurological Therapy’s 9th annual meeting, J&J said.
Johnson & Johnson said that the Cerenovus product portfolio aims to help improve stroke care, with the number of strokes annually projected to rise from 1.1 million in 2000 to 1.5 million by 2025.
“We believe stroke should not be a life sentence. Cerenovus is inspired by our long heritage ...
Source: Mass Device - September 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neurological cerenovus johnsonandjohnson Neuravi Limited Pulsar Vascular Source Type: news
J & J ’ s Codman Neuro picks up Pulsar Vascular
Johnson & Johnson‘s (NYSE:JNJ) Codman Neuro said last week it picked up Pulsar Vascular, which produces the PulseRider device for treating brain aneurysms, for an undisclosed amount.
The PulseRider is designed to shore up the blood vessels around wide-necked aneurysms at or near a bifurcation of the basilar tip or carotid terminus and facilitate the implantation of an embolization coil, without obstructing blood flow through the vessels, according to the company’s website.
Codman Neuro said the acquisition will complement its portfolio of products covering hemorrhagic and ischemic stroke.
“There is a signif...
Source: Mass Device - December 13, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Vascular Codman Neuro Johnson and Johnson Pulsar Vascular Source Type: news
MassDevice.com +5 | The top 5 medtech stories for November 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Final FDA rules clarify adverse event reporting for contract manufacturers
The FDA last week issued final guidance for medical device companies on the requirements for reporting adverse events that walked back much of the burde...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
MassDevice.com +5 | The top 5 medtech stories for May 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Xtant Medical amends Orbimed credit line to $15m, taps restructuring advisors
Xtant Medical said today that it amended its senior credit line with OrbiMed Advisors, saying it plans to use the $15 million facility to pay off the ...
Source: Mass Device - May 12, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Boston Scientific closes $270m Claret Medical buy
Boston Scientific (NYSE:BSX) said yesterday that it closed the $270 million buyout of Claret Medical and its Sentinel device, including a $50 million earnout pegged to a reimbursement win that just came in.
Claret’s Sentinel device is designed to trap and remove debris dislodged during transcatheter aortic valve replacements to prevent stroke and other neurological damage. The deal, announced July 20, originally called for an up-front cash payment of $220 million plus the $50 million reimbursement milestone.
That milestone was reached when the Centers for Medicare & Medicaid Services granted a New Technology Add...
Source: Mass Device - August 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Claret Medical Inc. Source Type: news
Medtronic to pay $51m to settle Covidien, ev3 DoJ investigations
Medtronic (NYSE:MDT) said yesterday that it agreed to pay $50.9 million to settle a number of U.S. Dept. of Justice probes into marketing activities from companies it acquired, Covidien and ev3.
Medtronic said that its subsidiary ev3, acquired when the Fridley, Minn.-based medtech giant picked up Covidien in 2015, agreed to plead guilty to a misdemeanor charge related to its marketing of the Onyx Liquid Embolic System, pay $17.9 million and adopt new compliance and reporting terms for three years.
The charges relate to ev3’s marketing of the device for “unproven and potentially dangerous uses,” federal prose...
Source: Mass Device - December 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Legal News Medtronic Source Type: news
IschemaView launches Rapid Angio neuroimaging system
Medical imaging dev IschemaView said yesterday that it launched its Rapid Angio neuroimaging system designed for use in the angiography suite.
The Menlo Park, Calif.-based company said that it partnered with Siemens (NYSE:SI) to integrate the Rapid software with Siemens’ SyngoDynaCT multiphase system for the newly launched imaging solution.
Siemens’ SyngoDyna CT Multiphase is a 3D image acquisition technique which uses multiple rotations of a C-arm system to acquire multi-phasic 3D representation of the brain and its perfusion.
“The Rapid Angio module, by combining the best-in-class syngoDynaCT system...
Source: Mass Device - March 1, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Imaging Neurological ischemaview Source Type: news
Medtronic acquires Covidien in a $43 billion deal | Medtech Wall Street news for the week of June 16, 2014
Here's a look at some of the top Wall Street stories for medical device companies this week: Blockbuster: Medtronic in $43B deal to acquire Covidien; Medtronic buyout holds $80M in golden parachutes for Covidien execs; FDA wants another panel hearing on Boston Scientific's Watchman anti-stroke device; European Commission tables review of Zimmer's $13B acquisition of Biomet; Ackman takes Allergan to court to defend against poison pill
Blockbuster: Medtronic in $43B deal to acquire Covidien
June 16, 2014 by Brad Perriello
Zimmer Holdings, Biomet, Boston Scientific, Covidien, European Commission, Food & Drug ...
Source: Mass Device - June 19, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news
